NeurAxis offers FDA-cleared IB-Stim device for pediatric IBS pain. Despite positive advancements, market recognition lags.

ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two ...

("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, ...

MindHYVE.ai is a leader in domain-specific AI models and AGI agents, redefining operational excellence with smarter ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and ...

NeurAxis reported a 50% revenue increase in Q4 2024, reaching approximately $800,000, with a cash balance of $3.7 million. NeurAxis, Inc. reported a significant revenue increase of approximately ...

Revenues for 4Q24 were approximately $800 thousand, an increase of 50% compared to 4Q23. Revenues for FY2024 were approximately $2.7 million, an increase of 11% compared to FY2023. The Company had ...

Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical ...